Contineum holder plans $41.8K CTNM stock sale

A shareholder associated with Contineum Therapeutics, Inc. files a Rule 144 notice to sell 2,500 shares, following prior 10b5-1 plan sales.

Rhea-AI Filing Summary

Contineum Therapeutics, Inc. (CTNM) reports that securities associated with Carmine Stengone are being notified for potential sale under Rule 144. The notice covers a planned sale of 2,500 shares of common stock on September 8, 2026, following recent 10b5-1 sales over the prior three months.

Key Figures

Planned shares to be sold: 2,500 shares Planned sale dollar amount: $41,750.00 10b5-1 sale on August 3, 2026: 2,500 shares; $40,029.00 +2 more

5 metrics

Planned shares to be sold 2,500 shares Common stock sale associated with option exercise on September 8, 2026

Planned sale dollar amount $41,750.00 Associated with 2,500 shares of common stock on September 8, 2026

10b5-1 sale on August 3, 2026 2,500 shares; $40,029.00 Common stock sold under 10b5-1 plan

10b5-1 sale on July 8, 2026 2,500 shares; $40,000.00 Common stock sold under 10b5-1 plan

10b5-1 sale on June 30, 2026 10,000 shares; $160,080.00 Common stock sold under 10b5-1 plan

Key Terms

Rule 144, 10b5-1, Exercise of Stock Options

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

10b5-1 regulatory

"10b5-1 Sales for CARMINE STENGONE 3565 General Atomics Court"

A 10b5-1 plan is a pre-set schedule that lets company insiders buy or sell shares according to written instructions made when they do not possess material, nonpublic information. Think of it as a timed automatic payment for stock trades: it helps insiders avoid accusations of trading on secret information and gives outside investors a clearer signal about whether sales are routine or potentially informative about the company’s prospects.

Exercise of Stock Options financial

"Common | 09/08/2026 | Exercise of Stock Options | Issuer"

FAQ

What does the Form 144 filing for CTNM disclose about planned share sales?

The Form 144 filing discloses a planned sale of 2,500 shares of Contineum Therapeutics, Inc. common stock on September 8, 2026, in connection with the exercise of stock options, with the sale to be made for cash through a broker.

Who is the selling security holder in the CTNM Form 144 filing?

The selling security holder is Carmine Stengone, for whose account the Contineum Therapeutics, Inc. common stock is to be sold under Rule 144. The securities relate to the exercise of stock options and subsequent sale for cash.

How many CTNM shares has Carmine Stengone sold in the past three months?

The filing lists prior 10b5-1 sales of Contineum Therapeutics, Inc. common stock totaling 15,000 shares: 2,500 shares on August 3, 2026, 2,500 shares on July 8, 2026, and 10,000 shares on June 30, 2026.

What were the dollar amounts for the recent CTNM 10b5-1 share sales?

The recent 10b5-1 sales of Contineum Therapeutics, Inc. common stock reported were for $40,029.00 on August 3, 2026, $40,000.00 on July 8, 2026, and $160,080.00 on June 30, 2026, corresponding to sales of 2,500, 2,500, and 10,000 shares, respectively.

What is the aggregate dollar value of the CTNM shares planned for sale on September 8, 2026?

For the planned September 8, 2026 transaction, the Form 144 indicates 2,500 shares of Contineum Therapeutics, Inc. common stock with an associated dollar amount of $41,750.00, in connection with an exercise of stock options and sale for cash.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/08/2026 - 04:29 PM Accepted by SEC EDGAR 09/08/2026 - 04:28 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001861519
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Contineum Therapeutics, Inc.
SEC File Number	001-42001
Address of Issuer	3565 General Atomics Court, Suite 200 San Diego CALIFORNIA 92121
Phone	8583335280
Name of Person for Whose Account the Securities are To Be Sold	CARMINE STENGONE
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	2500	41750.00	32958632	09/08/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/08/2026	Exercise of Stock Options	Issuer			2500	09/08/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for CARMINE STENGONE 3565 General Atomics Court, Suite 200 San Diego CA 92121	Common	08/03/2026	2500	40029.00
10b5-1 Sales for CARMINE STENGONE 3565 General Atomics Court, Suite 200 San Diego CA 92121	Common	07/08/2026	2500	40000.00
10b5-1 Sales for CARMINE STENGONE 3565 General Atomics Court, Suite 200 San Diego CA 92121	Common	06/30/2026	10000	160080.00

144: Remarks and Signature

Remarks
Date of Notice	09/08/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	09/23/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Carmine Stengone
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)